Livzon Pharmaceutical Group (HKG:1513, SHE:000513) completed the cancellation of a total of 6,667,795 unexercised share options, a Tuesday Hong Kong bourse filing said.
The options were issued under a 2022 share options incentive scheme, according to the Chinese pharmaceutical company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.